New Weekly System Can Track Severe Pneumococcal Infections

A real-time surveillance system in Denmark, tracking both invasive and noninvasive pneumococcal infections, showed better monitoring of disease trends and vaccine effectiveness, according to a study published in the Journal of Infection.¹

“Streptococcus pneumoniae (pneumococcus) is a leading cause of community-acquired pneumonia and, despite the availability of several pneumococcal vaccines, pneumococcal pneumonia is still a major contributor of morbidity and mortality worldwide,” wrote the authors of the study. “Surveillance is crucial for monitoring incidence of invasive pneumococcal disease (IPD), serotype dynamics, vaccine effectiveness, and potential vaccine failure.”

In a major leap forward for respiratory disease monitoring, researchers in Denmark have successfully implemented an automated, weekly updated surveillance system that tracks both invasive and noninvasive pneumococcal infections in near real-time. This innovative register-based approach—which utilizes national electronic health records—marks a significant departure from traditional models that often only capture the most severe and invasive cases.¹

READ MORE: Data Suggest Resurgence of Pneumococcal Serotype Despite Vaccination

For pharmacists, who serve as vital frontline providers for both adult immunizations and antibiotic stewardship, this high-frequency data offers a clearer picture of the total disease burden caused by pneumococcus.^1,2

The new Danish system identifies cases of pneumococcal severe acute respiratory infection (SARI) by linking hospital admission data with microbiological test results retrieved from a national database. Although established systems, like the CDC’s Active Bacterial Core surveillance (ABCs) or the National Notifiable Diseases Surveillance System, primarily track IPD—where bacteria are found in normally sterile sites like the blood or cerebrospinal fluid—the Danish model also captures noninvasive pneumonia.^1,3,4

This is critical because noninvasive infections are estimated to be 3-to-4-times more common than invasive cases, accounting for a substantial portion of the overall public health burden.¹

From a clinical perspective, the data gathered over a 10-year study period (2015-2025) highlight significant differences in patient outcomes based on the type of infection. Patients with invasive pneumococcal SARI generally face more severe disease, characterized by longer hospital stays, a higher frequency of intensive care treatment, and a 30-day mortality rate that can reach over 21% in adults aged 80 and older.

Conversely, those with noninvasive infections were often younger, more likely to have underlying lung disease, and frequently presented with viral co-infections such as influenza or respiratory syncytial virus (RSV). Understanding these epidemiological shifts is essential for pharmacists as they consult with high-risk patients and manage the complexities of antibiotic resistance, which currently affects more than 40% of IPD cases in some regions.^1,4

According to BMC Proceedings, the push for more integrated, real-time data visualization surged during the COVID-19 pandemic, leading to a global proliferation of respiratory pathogen dashboards. Although these tools offer actionable insights for public health decision-making, experts note that they face persistent challenges regarding data standardization, staffing shortages, and the need for sustainable IT infrastructure.⁵

The Danish system addresses some of these hurdles through automation, though maintaining such platforms still requires dedicated oversight to ensure data quality and transparency.^1,5

Global initiatives underscore the importance of serotype-specific surveillance to evaluate the long-term impact of pneumococcal conjugate vaccines (PCV10/13). Because the distribution of serotypes differs across geographical areas and populations, real-time tracking allows health authorities to identify trends in serotype replacement, where non-vaccine strains increase as vaccine-targeted strains decline.^3,6

This information is paramount for pharmacists who are increasingly responsible for administering the latest iterations of vaccines, including PCV15, PCV20, and PCV21—ensuring that adult patients remain protected as local epidemiology evolves.^1,2,6 As the field moves toward multi-pathogen surveillance, systems that offer weekly insights will be indispensable for monitoring vaccine effectiveness and guiding the clinical response to both seasonal threats and emerging pathogens.^1,5

“We have built a new approach for weekly register-based national surveillance that captures both non-invasive and invasive pneumococcal SARI,” concluded the authors of the current study.¹ “This surveillance system is now part of the national surveillance of SARI and allows for a near real-time monitoring of trends in disease burden of several respiratory pathogens including also SARS-CoV-2, influenza A/B, RSV, and mycoplasma pneumoniae, as well as evaluating public health measures such as effects of vaccination.”

READ MORE: Pneumococcal Resource Center

Don’t get left behind: Sign up today for our free Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips delivered straight to your inbox.

REFERENCES

1. Lomholt FK, Valentiner-Branth P, Nielsen RT, et al. A real-time register-based surveillance system for non-invasive and invasive pneumococcal disease. J Infect. April 4, 2026:106744. https://doi.org/10.1016/j.jinf.2026.106744

2. Pneumococcal vaccination. CDC. February 25, 2026. Accessed April 7, 2026. https://www.cdc.gov/pneumococcal/vaccines/index.html

3. Disease information about pneumococcal disease. European Centre for Disease Prevention and Control. November 28, 2023. Accessed April 7, 2026. https://www.ecdc.europa.eu/en/pneumococcal-disease/facts

4. Pneumococcal disease surveillance and trends. CDC. February 25, 2026. Accessed April 7, 2026. https://www.cdc.gov/pneumococcal/php/surveillance/index.html

5. Halley A, Schneeberger C, Stelma FF, et al. Respiratory virus surveillance in the post-pandemic era: challenges and opportunities for dashboard-based public health action. BMC Proc. 2026 Mar 16;20(Suppl 13):10. doi: 10.1186/s12919-026-00368-2. Erratum in: BMC Proc. 2026 Apr 2;20(1):17. doi: 10.1186/s12919-026-00372-6.

6. Deloria Knoll M, Bennett JC, Garcia Quesada M, et al. Global landscape review of serotype-specific invasive pneumococcal disease surveillance among countries using PCV10/13: the pneumococcal serotype replacement and distribution estimation (PSERENADE) project. Microorganisms. 2021 Apr 2;9(4):742. doi: 10.3390/microorganisms9040742.